Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

Gartner may be a biotech genius and a business wizard.

But you say he already has the license to manufacture and sell DR-70, and in six weeks when the patent expires he won't even need THAT.

He already has Radient's only asset, as short-lived as that asset may be. So there is NO REASON for Gartner or Provista or anyone else to acquire RXPC stock or take over Radient as a company. No reason at all. If they want a shell to get listed on an exchange, they merely need to find a Dignyte somewhere that has no debt and hasn't issued all of its authorized shares.